Exploring the current status of neuroendocrine tumours: a population-based analysis of epidemiology, management and use of resources by Darbà, Josep & Marsà, Alícia
RESEARCH ARTICLE Open Access
Exploring the current status of
neuroendocrine tumours: a population-
based analysis of epidemiology,
management and use of resources
Josep Darbà1* and Alicia Marsà2
Abstract
Background: Neuroendocrine tumours (NETs) are rare malignancies characterised by its capacity to synthesise and
secrete monoamines, due to its neuroendocrine origin. Its varied locations and symptoms have traditionally been
responsible for extended delays in their diagnosis. The interest of this study was to characterise the patient
population diagnosed with NETs in Spain and to revise how the disease is managed, together with the
hospitalisation costs of these patients.
Methods: The database included records of all patients diagnosed with a NET between 2010 and 2015. Admission
records were used to evaluate hospitalisation, disease management data and costs, and single-patient files were
used to characterise the population.
Results: Nine Thousand One Hundred Twenty patients were diagnosed with a neuroendocrine tumour between
2010 and 2015, with a 2 fold increase in the diagnosis rate over the study period. 42.25% of the patients were
females, while 57.75% were males, and mean diagnosis age was 62.58 years (SD = 14.65). Considering all the
registered neuroendocrine neoplasms, 46.86% of the patients had malignant well-differentiated NETs, 32.02% had a
malignant poorly differentiated neuroendocrine carcinoma and 42.93% of patients developed metastatic NETs. In
addition, 18.59% of patients were diagnosed with benign well-differentiated NETs. The most common tumour sites
were the bronchus, lung and other sites, including pancreatic tumours; metastasis was found in the liver and
distant lymph nodes. Pancreatic resection was the most common surgical procedure utilised in these patients,
summing 19% of total expenses, the injection of an unspecified therapeutic substance (including targeted
therapies) was registered in 11.40% of admissions, while chemotherapy was registered in only 6.85% of admissions.
The annual healthcare cost of NETs was €15,373,961, corresponding to €9092 per patient.
Conclusions: The implementation of standard diagnosis procedures should be prioritised, with a focus on the
pancreas and lung, and taking into account that 42.93% of the patients develop a metastatic tumour. The presence
of comorbidities and multimorbidities should be considered in order to develop more efficient disease
management protocols.
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Background
Neuroendocrine tumours (NETs) are a type of neo-
plasms characterised by its capacity to synthesise and se-
crete monoamines, due to its neuroendocrine origin [1].
NETs are classified according to various features centred
on their biological behaviour: grade, differentiation and
stage, and by their location [2]. The body-wide distribu-
tion of NETs is explained by the extensive presence of
neuroendocrine tissue in the human body. Several stud-
ies described the lung, pancreas and the gastrointestinal
tract as the primary sites to find these tumours, although
they can appear in numerous areas generating a variety
of symptoms that are diverse, being it complex to associ-
ate them directly to the disease [3]. Moreover, functional
tumours cause a series of symptoms, known as carcinoid
syndrome, primarily affecting the digestive and respira-
tory systems, the skin and the heart [1].
NETs are considered rare tumours. Data collected over
the past 20 years in several European countries and the
USA estimated an incidence of 1–5 per 100,000 inhabitants
[4], with an increasing tendency over the past years [5].
Their rarity, together with their body-wide presenta-
tion and variability, is responsible for the delays in diag-
nosis that occur frequently. A delay of 52 months on
average has been reported in patients with NETs be-
tween the first symptoms and diagnosis, and it is com-
mon for patients to be examined by several different
doctors before receiving the correct diagnosis [6], thus
the interest on reviewing the characteristics of affected
patients, tumour nature and managing. Altogether, ef-
forts are made to facilitate timely diagnosis, referral and
disease management.
Currently, curative treatment depends on the tumour
location and generally consists of the resection of the
tumour and adjacent tissue that can be accompanied
with adjuvant chemotherapy in intermediate and high
grade NETs [7–13], other treatments for the control of
symptoms are somatostatin analogues or the use of tar-
geted therapies [14]. The therapeutic choice is based on
tumour characteristics and most patients require a
multidisciplinary care. Still, in some cases tumour behav-
iour may not correspond with its histology, which leaves
patients and professionals with no clear guidelines [1].
Traditionally, a correct and rapid diagnosis of NETs has
been challenging due to their indolent history and het-
erogeneous pathology but with the recent advances in
the histopathological characterisation of NETs, diagnosis
is becoming accurate and timely, which could be behind
their increasing incidence.
The objective of this study was to revise the current
state of NETs in Spain, reviewing not only patient and
disease characteristics but also disease management pro-
tocols and efficiency. NETs economic impact associated
with healthcare usage has also been evaluated.
Methods
Data extraction
Patient records were extracted from the database under
the supervision of the Spanish Ministry of Health, which
compiles information from 192 private and 313 public
hospitals, covering all Spanish regions. Patients admitted
with a neuroendocrine neoplasm in secondary care
(inpatient and outpatient) between 2010 and 2015 were
identified with the code 209 from the 9th revision of the
International Statistical Classification of Diseases and
Related Health Problems, Clinical Modification (ICD9-
CM). Prior to the extraction, parameters such as health
centres and medical history identifiers were re-coded to
maintain records anonymised in accordance with the
principles of Good Clinical Practice and the Declaration
of Helsinki, and thus, ethics committee approval was
not required (Ley 14/2007, de 3 de julio, de Investiga-
ción biomédica).
Data analysis
All admission data was used to evaluate information
on hospital admission and discharge, days of stay,
services that attended the patients, and medical
procedures utilised. The extraction of single-patient
information was carried out to analyse patient charac-
teristics by eliminating repeated records correspond-
ing to separated admissions, relying on the first
admission as the index event.
Within the database, tumours were codified and
classified following the ICD9 criteria, firstly according
to their behaviour and in malignant well-differentiated
NETs, malignant poorly differentiated neuroendocrine
carcinomas (NECs), benign well-differentiated NETs
and metastatic neuroendocrine tumours (mNETs).
Then, tumours were classified according to their ori-
gin site. ICD9-CM codes identified patient diagnoses,
and medical procedures data was claimed by means of
the 9th revision of the International Statistical Classifica-
tion of Diseases and Related Health Problems, Procedure
Classification System (ICD9-PCS). The expenses associ-
ated with secondary healthcare were calculated based on
the mean costs of medical procedures determined by the
Spanish ministry of health, which include the costs related
to medical examination, all in-hospital medication, sur-
gery, nutrition, personnel, medical equipment and re-
sources in both inpatient and outpatient admissions. The
individual cost of somatostatin analogues and targeted
therapy could not be calculated due to the lack of a spe-
cific ICD9-PCS code and the costs of prescription drugs
were not available in this database.
Data presentation is mainly descriptive. Statistical
analyses were performed using Microsoft Excel© Pro-
fessional Plus 2010 (Microsoft Corporation, Redmond,
WA, USA).
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Results
Patient characteristics
Between 2010 and 2015, 9120 patients were diagnosed
with a neuroendocrine neoplasm, with an increasing
tendency over the years (Fig. 1a). A 2 fold increase was
observed in the number of diagnosed patients over a 6
year period. Overall, females represented the 42.25% of
these patients, while males were the 57.75%. The differ-
ent types of neoplasms were diagnosed at a mean age of
62.58 years (SD = 14.65), with virtually no differences
between males and females. Tumours were diagnosed in
patients ranging from 1 to 104 years, and the analysis
per age groups revealed a peak in the group of patients
between 66 and 70 years old (Fig. 1b).
The database permitted the analysis of tumour typology,
considering that one patient could be diagnosed with
distinct tumour types. In total, 12,804 neoplasms were
registered; 46.86% of the patients had a malignant NET,
32.02% had a poorly differentiated NEC and 42.93% of
patients developed mNETs (Table 1). In addition, 18.59%
of patients were diagnosed with benign neuroendocrine
tumours.
The most common NETs were those of the bronchus
and lung and of other sites, which includes pancreatic
tumours, mNETs were principally tumours of the liver
and distant lymph nodes and for malignant poorly differ-
entiated neuroendocrine tumours site was generally not
specified.
In all cases, neuroendocrine neoplasms and metastatic
tumours were the hospitalisation motive; yet, secondary
diagnoses registered during the admission were also
available. Disease comorbidities affecting more than 5%
of patients were analysed to further characterise the
population (Table 2). In total, 41.62% of the patients had
essential hypertension, 18.38% were diagnosed with dia-
betes mellitus (type I or II), and other disorders that
may influence patients treatment were observed, as an-
aemia, hypercholesterolemia, chronic airway obstruction
or renal failure. Additionally, tumour metastases were
registered in a large number of patients; presumably
attributable to metastatic neuroendocrine tumours af-
fecting principally the liver, lymph nodes and bone.
Healthcare usage and disease management
Between 2010 and 2015, 11,637 admissions were regis-
tered in the database corresponding to patients affected
by neuroendocrine neoplasms. Less than one admission
was registered per patient per year and mean hospitalisa-
tion time was of 11 days. The average readmission rate,
understood as a readmission attributable to the same
motive within 30 days after discharge, was 16.10%.
To assess disease management several parameters were
evaluated, including admission origin, the service to attend
the patients, medical procedures, and patients’ condition
at discharge. According to the registry, 55.99% of hospital
admissions corresponded to scheduled visits, while 43.83%
were non-scheduled or urgent. After discharge, the vast
majority of patients were discharged into their residence,
83.94%, less than 2% of patients were transferred to other
hospitals or extended care facilities, while 12.66% of pa-
tients died during the hospitalisation event.
Oncology services registered 19.56% of the admissions,
followed by admissions into digestive surgery services,
18.86% (Fig. 2).
The analysis of the common medical procedures
showed a persistent presence of diagnostic procedures,
especially focused on the abdomen and thorax, and a
propensity to surgically remove tumours and affected
regions (Table 3). Interestingly, the injection of chemo-
therapy was registered in only 6.85% of total admissions.
The injection of other therapeutic substances was regis-
tered in 11.40% of admissions, which is likely to include
somatostatin analogues and targeted therapies. On the
other hand, pulmonary lobectomies and operations were
a minority, which suggests that other treatment options
were considered for bronchus and lung NETs. A further
analysis showed that only 7% of patients with malignant
lung NETs were subjected to lobectomies and the same
percentage received chemotherapy, while about 10% of
patients received another therapeutic substance.
Fig. 1 a Patients diagnosed with NETs per year in Spain. b % of patients diagnosed per age group
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Direct medical cost
The direct cost of NETs associated to the use of health-
care resources in secondary care (inpatient and outpatient)
was €15,373,961 per year, corresponding to €9093 per pa-
tient per year between 2010 and 2015. Within this cost,
surgical procedures, and chemotherapy and radiotherapy
administration accounted for most of the expenses
(Table 4). The individual cost of somatostatine analogues
and targeted therapy could not be assessed. Patients with
malignant NETs of the ileum, cecum, thymus, benign
NETs of the transverse colon and other sites (including
pancreas) displayed the highest costs per patient.
In addition, 98.39% of the patients were attended
under social security financing, and the number of pa-
tients under private or mutual care was less than 1%.
Table 1 Percentage of patients diagnosed per specified tumour
type
Tumour classification (ICD9-CM) % of patients
Malignant neuroendocrine tumours
(Well- differentiated), (low grade NET)
(carcinoid), (intermediate grade NET)
(atypical carcinoid), (high grade NET)
(atypical carcinoid).
46.86
209.0 Small intestine 6.95
209.1 Appendix, large intestine,
and rectum
5.05
209.2 Other and unspecified sites 34.86
209.20 Unknown primary site 2.46




209.25 Foregut, not otherwise specified 0.60
209.26 Midgut, not otherwise specified 2.15
209.27 Hindgut, not otherwise specified 0.29
209.29 Other sites not elsewhere classified 8.46
209.3 Malignant poorly differentiated
neuroendocrine carcinomas
(High grade NEC not otherwise
specified), (small cell lung carcinoma),
(small cell uterine carcinoma), (small
cell neuroendocrine carcinoma),
(large cell neuroendocrine carcinoma),
(Merkel cell carcinoma).
32.02
209.30 Malignant poorly differentiated
NEC, any site
28.16
209.31 Merkel carcinoma of the face 1.03
209.32 Merkel carcinoma of the scalp and neck 0.31
209.33 Merkel carcinoma of the upper limb 0.56
209.34 Merkel carcinoma of the lower limb 0.68
209.35 Merkel carcinoma of the trunk 0.29
209.36 Merkel carcinoma of the buttock,
genitals and others not elsewhere classified
1.00
Benign neuroendocrine tumours
(Well- differentiated, (low grade NET)
(carcinoid), (intermediate grade NET)
(atypical carcinoid).
18.59
209.4 Small intestine 1.23
209.5 Appendix, large intestine, and rectum 2.08
209.6 Other and unspecified sites 15.27
209.60 Unknown primary site 2.37




209.65 Foregut, not otherwise specified 0.33
209.66 Midgut, not otherwise specified 1.07
Table 1 Percentage of patients diagnosed per specified tumour
type (Continued)
Tumour classification (ICD9-CM) % of patients
209.67 Hindgut, not otherwise specified 0.60
209.69 Other sites not elsewhere classified 2.80
209.7 Secondary or metastatic
neuroendocrine tumours
42.93
209.70 Unspecified site 0.32




209.75 Secondary Merkel cell carcinoma 0.93
209.79 Other sites not elsewhere classified 9.17
Table 2 Disease comorbidities affecting more than 5% of the
patients
Disease comorbidities % of patients
Unspecified essential hypertension 41.62
Liver metastases 29.42
Diabetes mellitus (type I or II) 18.38
Unspecified hyperlipidaemia 18.33
Lymph nodes metastases 18.23
Respiratory failure and chronic airway obstruction 10.90
Bone metastases 10.69
Renal failure and chronic kidney disease 9.85
Anaemia 9.22




Neoplasm related pain 5.48
Obesity 5.37
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Discussion
Patient characteristics
The prevalence of NETs in the general population has
just recently started being evaluated. These malignancies
are overall rare, although research suggest an increase in
their diagnosis. A previous retrospective study in Canada
displayed a marked increase, of 2.5 fold, of NETs inci-
dence over the course of 15 years [5], comparable to that
found herein, probably a consequence of the improve-
ment in their detection. Disease predominance in males
has been as well previously described, similarly to the
peaking incidence in patients over 65 years [3]. A large
number of patients, 78.88%, had a malignant neoplasm,
considering NETs and NECs, and the importance of tu-
mours in the bronchus and lung and the gastrointestinal
tract support previous evidence that should direct re-
search and diagnostic advances [1, 6].
The presence of comorbidities as essential hypertension
and diabetes possibly reflects the ageing nature of the
population of study, as for hyperlipidaemia. Alternatively,
metabolic disorders have been described in patients
treated with certain inhibitors of serine/threonine-specific
protein kinases [15]. The present database does not in-
clude information regarding patients’ state prior to diag-
nosis; nonetheless, a previous presence of obesity and
metabolic syndrome has been linked with NETs incidence
which would require further research [16]. Altogether, co-
morbidities have a direct influence in the therapeutic
choice [2] and should be considered in the principal med-
ical protocols.
Healthcare usage and disease management
The use of molecular tumour markers was not evaluable
via this database, although, as expected, diagnostic im-
aging procedures were preferred in patients with sus-
pected NETs, favouring tomography or MRI techniques
[2]. Secondarily, biopsies were employed. In terms of
Fig. 2 Services to admit patients with NETs in Spain (2010–2015)
Table 3 Management of NETs: Most common medical
procedures used to diagnose and treat patients






Radiography of abdomen or thorax 2212 19.01
Echography of abdomen or
digestive system
1615 13.88
Magnetic resonance imaging (MRI) 695 5.97
Surgery
Total or partial pancreatectomy 745 6.40
Partial resection of the intestine 498 4.28
Total or partial cholecystectomy 426 3.66
Total or partial splenectomy 338 2.90
Partial hepatectomy 134 1.15
Treatment






Antibiotic injection 992 8.52
Palliative care 511 4.39
Steroid injection 364 3.13
Anticoagulant injection 308 2.65
Blood transfusion 182 1.56
Table 4 Annual healthcare usage costs of NETs in Spain





Major pancreatic surgery €2,985,369
Major intestine surgery €885,885
Cholecystectomy €874,288
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treatment, surgery appeared as the primary therapeutic
option, and pancreatectomies were predominant, which
indicates a prevalence of pancreatic tumours in these pa-
tients although the exact number could not be deter-
mined due to the lack of a specific code for this site.
Less than one new admission per year was registered
after the diagnosis of a NET, yet the readmission rate
was 16.10%. Previous follow-up studies suggest that
readmissions are likely related to postoperative compli-
cations after pancreatectomy [17], and patients’ admis-
sions into oncology or surgery services are in line with
cancer management protocols. The percentage of regis-
tered chemotherapy sessions was surprisingly low; it is
possible that its importance was diluted in total admis-
sion data, nonetheless limitations due to the database
characteristics cannot be ruled out. Moreover, the data-
base characteristics impeded a direct analysis of the use
of targeted therapies and somatostatin analogues which
should be addressed in further studies; currently, the use
of these therapies is codified as the injection of another
therapeutic substance not specified in another code.
In terms of prognosis and survival, mortality rates vary
enormously with tumour characteristics. In patients with
pancreatic NETs 5-year survival rates of 53.9% have been
registered [18], although previous follow-up studies of
patients after aggressive resection suggest an increase in
the 5-year survival up to 80% [19]. To infer survival in
the population of study, discharge data was evaluated.
Herein patients’ mortality could only be measured when
it was registered during hospitalisation; yet, in-hospital
mortality reached the 12.66%.
Direct medical cost
The healthcare usage cost associated with NETs is largely
unknown, and it originates rising interest given the in-
creased number of diagnosis in the past years. Herein, the
€9093 per patient per year are the sum of the direct costs
of hospital admissions (inpatient and outpatient care) in-
cluding all medical procedures, with almost 3 million
euros destined to pancreatic surgery only, which repre-
sents 19% of total annual secondary care expenses for the
disease. A preceding study in the United States suggested
that those patients with pancreatic tumours account for
the highest costs [20]. Similarly, data obtained from a can-
cer registry in Canada supports this statement [21]. Our
data suggests that this cost could be linked to the resec-
tion of benign tumours. Primary care costs and pharma-
ceutical expenses should be considered in further analysis
to calculate the total medical costs of NETs. In addition,
Hallet and colleagues predicted an increase of treatment
costs over time due to drug maintenance therapy in pa-
tients with grastrointestinal NETs, obtaining an inpatient
care cost that reached the €9469 per patient at the time of
diagnosis [22].
Presumably, patients’ old age increases overall costs as it
raises the number of chronic diseases that are diagnosed
in these patients, given the augmented needs and high
costs that have been associated with multimorbidities in-
cluding diabetes, anaemia and hypertension [22, 23].
A series of factors limit the conclusions were subjected
to a series of limitations that derive from the database
characteristics. Data is codified via ICD9 codes that not
correlate with the most recent NET classification criteria
as expressed by the World Health Organisation. The
lack of specific ICD9 codes to identify somatostatin ana-
logues and targeted therapies impedes the quantification
of these drug-related costs individually. Equally, primary
care and pharmaceutical data was not available. This
study provides novel data on the minimal existing litera-
ture regarding the management of NETs and their costs;
nevertheless, further research will be required to deter-
mine the total burden that NETs represent for the Spanish
National Healthcare System.
Conclusions
A 2 fold increase was measured in the number of NETs
diagnoses between 2010 and 2015. All data suggest that
tumours primarily affect the pancreas, lung and the
gastrointestinal system, and that tumours are mainly
resected, which supposes an important portion of eco-
nomic costs. Herein, the use of adjuvant chemotherapy
was not generalised.
Standard diagnosis procedures should be implemented,
with a focus on the pancreas and lung, and taking into ac-
count that at least 78.88% of patients ultimately develop a
malignant tumour. Disease management protocols should
consider this data, together with disease comorbidities, in
order to develop more efficient treatment protocols.
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